




The relative strengths and weaknesses of Keryx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keryx Biopharmaceuticals INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 7.7% points. The greatest weakness of Keryx Biopharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 99% points.

The company's Economic Capital Ratio, given in the ranking table, is 125%, being 120% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	132,897
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	21,551
Liabilities, Non-Current	1,040
Other Assets	1,111
Other Compr. Net Income	0
Other Expenses	40,769
Other Liabilities	127,132
Other Net Income	-38,252
Other Revenues	31,983
Property and Equipment	4,211
Research and Development	29,504
Selling, General and Administrative Expense	84,553

Output Variable	Value in 1000 USD
Assets	141,427
Liabilities	149,723
Expenses	154,826
Revenues	31,983
Stockholders Equity	-8,296
Net Income	-161,095
Comprehensive Net Income	-161,095
BaseVar	258,106
ECR before LimitedLiability	-123%
Economic Capital Ratio	125%